Company: BIAF
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001641172-25-001840
Chunk: 771

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 7
Chunk 771
---
247,829 

    Non-current liabilities 

    Operating lease liability,
    net of current portion 
     342,098  
     283,001 
  
    Finance lease liability,
    net of current portion 
     444,448  
     835,467 
  
    Notes payable, net of current portion 
     20,180  
     — 

    Total liabilities 
     3,911,631  
     3,366,297 

    Commitments and contingencies (See Note
    11) 
     -   
     -  

    Stockholders’ equity: 

    Preferred stock, no
    shares issued or outstanding at December 31, 2024 and 2023, respectively 
     —  
     — 
  
    Common stock, par value
    $0.007 per share; 100,000,000 shares authorized; 15,576,674 and 9,394,610 shares issued and outstanding as of December 31, 2024 and
    2023, respectively 
     106,593  
     65,762 
  
    Additional paid-in capital 
     56,139,753  
     49,393,972 
  
    Accumulated
    deficit 
     (53,644,310) 
     (44,604,479)
  
    Total
    stockholders’ equity 
     2,602,036  
     4,855,255 

    Total liabilities, and
    stockholders’ equity 
    $6,513,667  
    $8,221,552 

The
accompanying notes are an integral part of these consolidated financial statements.

F-3

bioAffinity
Technologies, Inc.

Consolidated
Statements of Operations

For
the Years Ended December 31, 2024 and 2023

    2024  
    2023 

    Net
    Revenue 
    $9,362,022  
    $2,532,499 

    Operating expenses: 

    Direct costs and expenses 
     5,983,475  
     1,740,884 
  
    Research and development 
     1,461,227  
     1,467,936 
  
    Clinical development 
     321,655  
     256,